Aridis Pharmaceuticals, Inc. (ARDS)
After hours:
| Previous close | 0.3631 |
| Open | 0.3631 |
| Bid | 0.0000 x 1000 |
| Ask | 0.0000 x 1200 |
| Day's range | 0.3600 - 0.4289 |
| 52-week range | 0.3500 - 2.7700 |
| Volume | |
| Avg. volume | 1,648,663 |
| Market cap | 14.792M |
| Beta (5Y monthly) | 1.07 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.7500 |
| Earnings date | 29 Mar 2023 - 03 Apr 2023 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 6.00 |
- GlobeNewswire
Aridis Pharmaceuticals Announces $2.28 Million Registered Direct Offering of Common Stock
Los Gatos, Calif., March 14, 2023 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company, today announced that it has entered into a definitive agreement for the issuance and sale of an aggregate of 6,000,000 shares of the Company’s common stock at a purchase price of $0.38 per share in a registered direct offering. The closing of the offering is expected to occur on or about March 16, 2023, subject to the satisfaction of customary closing conditions. H.C. W
- GlobeNewswire
Aridis Meets Primary and Secondary Endpoints in Phase 2a Study of AR-501 in Cystic Fibrosis Patients
The study achieved high uptake of AR-501 in the respiratory tract at levels that were more than 50-fold higher than required for inhibition of the target bacteria P. aeruginosa LOS GATOS, Calif., March 13, 2023 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS) today announced preliminary top-line results from the randomized, double blinded, placebo-controlled Phase 2a study of AR-501, which evaluated the safety and pharmacokinetics of three ascending doses of AR-501 administered as
- Simply Wall St.
When Will Aridis Pharmaceuticals, Inc. (NASDAQ:ARDS) Breakeven?
With the business potentially at an important milestone, we thought we'd take a closer look at Aridis Pharmaceuticals...
